Review: The evolving world of GLP-1 agonist therapies for type 2 diabetes

Therapeutic Advances in Endocrinology and Metabolism

Volumn 1, Issue 2, 2010, Pages 61-67

  Baynes, Kevin C R ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

exenatide; GLP 1; liraglutide; obesity; taspoglutide; type 2 diabetes mellitus

Indexed keywords

ALBIGLUTIDE; BYDUREON; EXENDIN 4; GLIMEPIRIDE; GLITAZONE DERIVATIVE; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; INSULIN ASPART; INSULIN GLARGINE; LIRAGLUTIDE; LIXISENATIDE; METFORMIN; PLACEBO; SITAGLIPTIN; SULFONYLUREA DERIVATIVE; TASPOGLUTIDE; UNCLASSIFIED DRUG;

DIET THERAPY; DISEASE ASSOCIATION; DISEASE CONTROL; DRUG DOSE REDUCTION; DRUG HYPERSENSITIVITY; DRUG SAFETY; FOOD INTAKE; GASTROINTESTINAL SYMPTOM; GLUCAGON RELEASE; HUMAN; HYPOGLYCEMIA; INSULIN RELEASE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; STOMACH EMPTYING; THERAPY EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; VOMITING; WEIGHT REDUCTION;

EID: 79952858293     PISSN: 20420188     EISSN: None     Source Type: Journal    
DOI: 10.1177/2042018810375414     Document Type: Review

References (44)

1. Ahmad, S. and Swann, J. ( 2010) Exenatide and rare adverse events. N Engl J Med 358: 1969-1972.
2. Apovian, C.M., Bergenstal, R.M., Cuddihy, R.M., Qu, Y., Lenox, S., Lewis, M.S. et al (2010) Effects of exenatide combined with lifestyle modification in patients with type 2 diabetes. Am J Med 123: 468.
3. Astrup, A., Rössner, S., van Gaal, L., Rissanen, A., Niskanen, L., Al Hakim, M. et al (2009) Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet 374: 1606-1616.
4. Bjerre Knudsen, L., Madsen, L.W., Andersen, S., Almholt, K., de Boer, A.S., Drucker, D.J. et al (2010) Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology 151: 1473-1486.
5. Brubaker, P.L. (2010) Minireview: update on incretin biology: focus on glucagon-like peptide-1. Endocrinology 151: 1984-1989.
6. Buse, J.B., Henry, R.R., Han, J., Kim, D.D., Fineman, M.S. and Baron, A.D. ( 2004) Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 27: 2628-2635.
7. Buse, J.B., Rosenstock, J., Sesti, G., Schmidt, W.E., Montanya, E., Brett, J.H. et al (2009) Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 374: 39-47.
8. Butler, P.C., Dry, S. and Elashoff, R. (2010) GLP-1-based therapy for diabetes: what you do not know can hurt you. Diabetes Care 33: 453-455.
9. Chia, C.W., Carlson, O.D., Kim, W., Shin, Y.K., Charles, C.P., Kim, H.S. et al (2009) Exogenous glucose-dependent insulinotropic polypeptide worsens post prandial hyperglycemia in type 2 diabetes. Diabetes 58: 1342-1349.
10. DeFronzo, R.A. ( 2009) From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 58: 773-795.
11. DeFronzo, R.A., Ratner, R.E., Han, J., Kim, D.D., Fineman, M.S. and Baron, A.D. ( 2005) Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 28: 1092-1100.
12. Drucker, D.J. ( 2006) The biology of incretin hormones. Cell Metabolism 3: 153-165.
13. Drucker, D.J., Sherman, S.I., Gorelick, F.S., Bergenstal, R.M., Sherwin, R.S. and Buse, J.B. (2010) Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits. Diabetes Care 33: 428-433.
14. Froud, T., Faradji, R.N., Pileggi, A., Messinger, S., Baidal, D.A., Ponte, G.M. et al (2008) The use of exenatide in islet transplant recipients with chronic allograft dysfunction: safety, efficacy, and metabolic effects. Transplantation 86: 36-45.
15. Garber, A., Henry, R., Ratner, R., Garcia-Hernandez, P.A., Rodriguez-Pattzi, H., Olvera-Alvarez, I. et al (2009) Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 373: 473-481.
16. Heine, R.J., van Gaal, L.F., Johns, D., Mihm, M.J., Widel, M.H. and Brodows, R.G. ( 2005) Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Internal Med 143: 559-569.
17. Kendall, D.M., Riddle, M.C., Rosenstock, J., Zhuang, D., Kim, D.D., Fineman, M.S. et al (2005) Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 28: 1083-1091.
18. Kim, D., MacConell, L., Zhuang, D., Kothare, P.A., Trautmann, M., Fineman, M. et al (2007) Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. Diabetes Care 30: 1487-1493.
19. le Roux, C.W., Aylwin, S.J.B., Batterham, R.L., Borg, C.M., Coyle, F., Prasad, V. et al (2006) Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters. Ann Surgery 243: 108-114.
20. Marre, M., Shaw, J., Brandle, M., Bebakar, W.M.W., Kamaruddin, N.A., Strand, J. et al (2009) Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). Diabetic Med 26: 268-278.
21. Nauck, M., Duran, S., Kim, D., Johns, D., Northrup, J., Festa, A. et al (2007) A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. Diabetologia 50: 259-267.
22. Nauck, M., Frid, A., Hermansen, K., Shah, N.S., Tankova, T., Mitha, I.H. et al (2009 a) Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes. Diabetes Care 32: 84-90.
23. Nauck, M.A., Ratner, R.E., Kapitza, C., Berria, R., Boldrin, M. and Balena, R. (2009 b) Treatment with the human once-weekly glucagon-like peptide-1 analog taspoglutide in combination with metformin improves glycemic control and lowers body weight in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care 32: 1237-1243.
24. Parks, M. and Rosebraugh, C. (2010) Weighing risks and benefits of liraglutide-the FDA's review of a new antidiabetic therapy. N Engl J Med 362: 774-777.
25. Pratley, R.E., Nauck, M., Bailey, T., Montanya, E., Cuddihy, R., Filetti, S. et al (2010) Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet 375: 1447-1456.
26. Rachman, J., Barrow, B.A., Levy, J.C. and Turner, R.C. ( 1997) Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM. Diabetologia 40: 205-211.
27. Raman, V.S., Mason, K.J., Rodriguez, L.M., Hassan, K., Yu, X., Bomgaars, L. et al (2010) The role of adjunctive exenatide therapy in pediatric type 1 diabetes. Diabetes Care 33: 1294-1296.
28. Ratner, R.E., Maggs, D., Nielsen, L.L., Stonehouse, A.H., Poon, T., Zhang, B. et al (2006) Long-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over-weight metformin-treated patients with type 2 diabetes mellitus. Diabetes Obesity Metab 8: 419-428.
29. Rosenstock, J., Klaff, L.J., Schwartz, S., Northrup, J., Holcombe, J.H., Wilhelm, K. et al (2010) Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without prediabetes. Diabetes Care 33: 1173-1175.
30. Rosenstock, J., Reusch, J., Bush, M., Yang, F. and Stewart, M. ( 2009) Potential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes. Diabetes Care 32: 1880-1886.
31. Russell-Jones, D., Vaag, A., Schmitz, O., Sethi, B., Lalic, N., Antic, S. et al (2009) Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met + SU): a randomised controlled trial. Diabetologia 52: 2046-2055.
32. Saliba, J., Wattacheril, J. and Abumrad, N.N. (2009) Endocrine and metabolic response to gastric bypass. Curr Opin Clin Nutrition Metab Care 12: 1363-1950.
33. Sjostrom, L., Lindroos, A.K., Peltonen, M., Torgerson, J., Bouchard, C., Carlsson, B. et al (2004) Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 351: 2683-2693.
34. Smith, U. and Gale, E. (2009) Does diabetes therapy influence the risk of cancer? Diabetologia 52: 1699-1708.
35. Sourij, H., Schmölzer, I., Kettler-Schmut, E., Eder, M., Pressl, H., deCampo, A. et al (2009) Efficacy of a continuous GLP-1 infusion compared with a structured insulin infusion protocol to reach normoglycemia in nonfasted type 2 diabetic patients: a clinical pilot trial. Diabetes Care 32: 1669-1671.
36. Todd, J.F., Wilding, J.P.H., Edwards, C.M.B., Ghatei, M. and Bloom, S.R. ( 1997) Glucagon-like peptide-1 (GLP-1): a trial of treatment in non-insulin-dependent diabetes mellitus. Eur J Clin Investigation 27: 533-536.
37. Toft-Nielsen, M.B., Madsbad, S. and Holst, J.J. ( 1999) Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients. Diabetes Care 22: 1137-1143.
38. US Food and Drug Administration (2010) FDA Website Memo, http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022341s000TOC.cfm (accessed 25 January 2010).
39. Vilsbøll, T., Krarup, T., Madsbad, S. and Holst, J.J. ( 2002) Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients. Diabetologia 45: 1111-1119.
40. Vilsbøll, T., Zdravkovic, M., Le-Thi, T., Krarup, T., Schmitz, O., Courrèges, J.P. et al (2007) Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. Diabetes Care 30: 1608-1610.
41. Yoon, N., Cavaghan, M., Brunelle, R. and Roach, P. (2009) Exenatide added to insulin therapy: a retrospective review of clinical practice over two years in an academic endocrinology outpatient setting. Clin Therapeutics 31: 1511-1523.
42. Zander, M., Madsbad, S., Madsen, J.L. and Holst, J.J. ( 2002) Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and [beta]-cell function in type 2 diabetes: a parallel-group study. Lancet 359: 824-830.
43. Zinman, B., Gerich, J., Buse, J.B., Lewin, A., Schwartz, S., Raskin, P. et al (2009) Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met + TZD). Diabetes Care 32: 1224-1230.
44. Zinman, B., Hoogwerf, B.J., Garcia, S.D., Milton, D.R., Giaconia, J.M., Kim, D.D. et al (2007) The effect of adding exenatide to a thiazolidindione in suboptimally controlled type 2 diabetes. Ann Intern Med 146: 477-485.